ClinicalTrials.gg
RecruitingNCT07189325DESIRE MSUpdated Jun 23, 2026

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

A Phase 3 interventional study of Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) and Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) in Relapsing-Remitting Multiple Sclerosis (RRMS) and Anti-CD20 Therapy, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by University Hospital, Montpellier · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.

Planned enrollment
26th of 70
250 · median 154
Started
2026
with 2 others
Phase 3
33 of 82
3 open now
Primary completion
2031-06
later than 13 of 13 live
Registered
79th of 82
by date
Lead sponsor
3 of 82
University Hospital, Montpellier

Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 26th largest by planned enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2026, is one of 33 in phase 3, reaches primary completion later than 13 of the 13 other live ones, and was the 79th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, or all of them as a file.
02

Study summary

Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit/risk profiles have been introduced leading to dramatic changes in the prognosis of MS.

First, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability.

More recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis.

Anti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes.

Taking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis (RRMS)
  • Anti-CD20 Therapy

Keywords

  • Multiple Sclerosis
  • High efficacy therapies
  • de-escalation
  • adverse events
  • relapses
  • escalation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria :

  • Patients ≥40 years at inclusion
  • Patients with relapsing remitting multiple sclerosis at inclusion (according to 2017 McDonald criteria) treated with anti-CD20 for at least the last 3 years. For patients treated with IV ocrelizumab or rituximab at extended interval dosing, a maximum interval of 12 months between perfusions during the year before inclusion visit is required.
  • No evidence of disease activity for the last 3 years on anti-CD20 (No relapse AND no new/enlarged MRI lesion)
  • Brain MRI performed according to OFSEP protocol within a maximum of 6 months before randomization

Non-inclusion criteria :

  • Secondary or primary progressive MS at inclusion
  • Previous experience of treatment failure in patients treated with natalizumab, fingolimod, rituximab, ocrelizumab, mitoxantrone, alemtuzumab or cladribine
  • Treatment with high dose during the 30 days preceding inclusion
  • to MRI
  • Severely state
  • Current severe active infection
  • Known active
  • Severe heart failure ( Class IV) or severe, uncontrolled cardiac disease
  • Severe hepatic impairment ( class C)
  • Significantly impaired bone marrow function or significant anaemia, leukopenia, neutropenia or thrombocytopenia
  • Severe renal impairment undergoing dialysis
  • Severe hypoproteinaemia, e.g. in nephrotic syndrome
  • Current severe depression and/or suicidal ideation
  • Suspected or confirmed progressive multifocal leukoencephalopathy (PML)
  • Any condition that, in the opinion of the investigator, would interfere with the interpretation of patient safety or place the patient at high risk for treatment-related complications
  • Participation in another therapeutic trial in the last 6 months
  • Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship/curatorship)
  • All women of childbearing age not using effective during the study
  • Subjects not covered by public health insurance
  • Failure to obtain written after a reflection period
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Patients randomized in the experimental group will be treated with platform therapies (Dimethyl Fumarate, Diroximel fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) according to treatments' authorization from the day of randomization to M36.

    Drug: Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)

  • Active comparator
    Control Group

    Patients randomized in the control group will be treated every 6 months (or, up to one year, at the same interval dosing) for patients with anti-CD20 (ocrelizumab, rituximab) or every 4 weeks for patients with subcutaneous anti-CD20 (ofatumumab) from the day of randomization to M36.

    Drug: Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)

Interventions

  • DrugPlatform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)

    Patients randomized in the experimental group will be treated with platform therapies (Dimethyl Fumarate, Diroximel Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) according to treatments' authorization from the day of randomization to M36 described below. Patients will receive appropriate information and recommendation for the initiation of the chosen platform treatment as mention in the SmPC by treating neurologist or a member of the investigating team. If therapies are not tolerated, a therapeutic switch to other platform therapies will be possible. Any switch to a disease modifying therapy not listed as platform therapy will be considered as a major protocol deviation (see statistics). Patients are allowed to switch from any platform DMT to another platform DMT.

  • DrugAnti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)

    Patients randomized in the control group will be treated every 6 months (or at previous extended interval dosing) for patients with anti-CD20 (Ocrelizumab, Rituximab) or every 4 weeks for patients with subcutaneous anti-CD20 (Ofatumumab) from the day of randomization to M36. If therapies are not tolerated, a therapeutic switch to other anti-CD20 therapy will be possible. Any switch to a disease modifying therapy not listed as anti-CD20 therapy will be considered as major protocol deviation (see statistics). Patients are allowed to switch from any anti-CD20 to another anti-CD20.

06

What researchers measure

Primary outcomes

  1. Relapse

    Presence of at least one clinical relapse defined as new or worsening symptoms related to MS resulting in objective signs on neurological examination in the absence of any potential trigger not related to MS.

    Time frame: From Day 0 to Month 36

  2. New/enlarged MRI lesions

    New/enlarged T2/FLAIR lesion on MRI scans to assess MRI disease activity .

    Time frame: From Day 0 to Month 36

Secondary outcomes

  1. Relapse

    Presence of at least one clinical relapse defined as new or worsening symptoms related to MS resulting in objective signs on neurological examination in the absence of any potential trigger not related to MS

    Time frame: From Day 0 to Month 36

  2. Expanded Disability Status Scale (EDSS)

    EDSS to compare disability between both groups. This score is expressed from 0 (no disability) to 10 (multiple sclerosis-related death) and incorporates evaluation of the following neurological systems (pyramidal, sensory, cerebellar, sphincter, cognitive, and cranial pairs)

    Time frame: From Day 0 to Month 36

  3. Brain MRI (T2/FLAIR Lesions)

    MRI scans to compare new/enlarged T2/FLAIR lesions between both groups.

    Time frame: From Day 0 to Month 36

  4. Number of adverse events and severe adverse events

    To compare adverse events and severe adverse events between both groups.

    Time frame: From Day 0 to Month 36

  5. Number of infections and serious infections

    To compare infections and serious infections between both groups.

    Time frame: From Day 0 to Month 36

  6. B-cell count (CD19/CD20 B cells)

    B-cell count (CD19/CD20 B cells) to compare C• B-cells repopulation (CD19/CD20+ B-cells) between both groups.

    Time frame: From Day 0 to Month 36

  7. Serum immunoglobulin (IgG, IgA, IgM) levels

    Serum immunoglobulin (IgG, IgA, IgM) levels to compare • Immunoglobulin (IgG, A, M) levels changes between both groups.

    Time frame: From Day 0 to Month 36

Other outcomes

  1. Multiple Sclerosis Functional Composite (MSFC)

    MSFC including the 9-Hole Peg Test (9HPT), Timed 25 Foot Walk (T25FW), and Paced Auditory Serial Addition Test (PASAT) to compare functional disability between both groups.

    Time frame: From Day 0 to Month 36

  2. The Computerised Speed Cognitive Test (CSCT)

    CSCT a cognitive test to compare the detection of information speed disorders between both groups.

    Time frame: From Day 0 to Month 36

  3. Neurofilament Light Chains (sNfL) Serum Concentration

    Neurofilament Light Chains (sNfL) Serum Concentration to compare change of serum Neurofilament light chains bteween both groups.

    Time frame: From Day 0 to Month 36

  4. The 5 Level European Quality of Life 5 Dimensions (EQ5D-5L)

    EQ5D-5L questionnaire to compare the generic quality of life between both groups.

    Time frame: From Day 0 to Month 36

  5. MUSICARE

    MUSICARE, self-report questionnaire to compare the experience of both patients and caregivers of quality of care in MS between both groups.

    Time frame: From Day 0 to Month 36

  6. CD27+ memory B-cell count

    CD27+ memory B-cell count to compare CD27+ memory B-cells repopulation between both groups.

    Time frame: From Day 0 to Month 36

  7. Patient-level cost

    Healthcare consumption collected via data from the SNDS (French Health Insurance Database) to assess medico-economic impact.

    Time frame: From Day 0 to Month 36

07

Study locations

1 of 1 sites recruiting
  • Neurology Department, Hospital Gui de Chauliac
    Montpellier, 34295, France
    Recruiting
    • Xavier Ayrignac, Medical Doctor · Contactx-ayrignac@chu-montpellier.fr · +33 4 67 33 74 13
    • Xavier Ayrignac, Medical Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2031, 60 months after the start.

Of 38 phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 66. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Sep 23, 2025
StartActual
Jun 15, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189325
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Jun 15, 2026
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Jun 23, 2026

Study contacts

Xavier AYRIGNAC, Medical Doctor
Contact
x-ayrignac@chu-montpellier.fr
+33 4 67 33 74 13

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion